Engineered peptidic constructs metabolize amyloid β by self-assembly-driven reactions.

Area of Science:

• Biochemistry
• Peptide Design
• Neuroscience

Background:

• Amyloid beta (Aβ) aggregation is a hallmark of Alzheimer's disease.
• Proteolytic processing of Aβ involves enzymes like alpha-secretase.
• Targeting Aβ cleavage offers therapeutic potential.

Purpose of the Study:

• To design and characterize novel peptide-based constructs capable of cleaving amyloid beta (Aβ).
• To investigate the non-catalytic cleavage mechanism of these constructs at the alpha-secretase site.
• To explore the potential of these "artificial α-secretases" in Aβ degradation.

Main Methods:

• Design of small peptide-based constructs.
• Assaying selective recognition and cleavage of Aβ.
• Time-resolved MALDI-TOF mass spectrometry for analysis of cleavage products.

Main Results:

• Developed "artificial α-secretases" that selectively recognize and cleave Aβ.
• Initial cleavage occurred near the α-secretase site in a non-catalytic manner.
• Prolonged treatment led to cleavage at other Aβ processing sites.

Conclusions:

• Artificial α-secretases represent a novel strategy for targeting Aβ.
• These peptide constructs demonstrate selective and site-specific Aβ cleavage.
• Further investigation may lead to new therapeutic avenues for Alzheimer's disease.